Hemerion, a company specializing in the development of innovative cancer therapies, won the INPI 2024 Trophy in the “Partnership Research” category on November 27, 2024. Created in 1991, this prestigious competition, organized by the French National Institute of Industrial Property (INPI), rewards exemplary companies in terms of their intellectual property strategy. This trophy rewards the …
Hemerion once again supports the second French National Brain Cancer Day organized by five patient associations in Paris on December 2nd. The French National Brain Cancer Day took place on December 2, 2024 in Paris. This second edition is once again an opportunity to mobilize the general public, health professionals and institutions to improve the …
Hemerion, a company specializing in the development of innovative cancer therapies, has been selected as a finalist for the INPI 2024 trophies in the “Partnership Research” category. Created in 1991, this prestigious competition organized by the Institut National de la Propriété Industrielle (INPI) rewards companies with exemplary intellectual property strategies. This selection rewards the work …
The result of 20 years of basic and clinical research, Hemerion continues to develop new therapeutic approaches to improve cancer treatment.Since 2020, our R&D team has been building ambitious partnerships with several key players in public and private research.The collaboration with Lesaffre is part of this drive to accelerate our research through contact with other …
Hemerion Therapeutics will take stage at this year’s Society of Neuro-Oncology (SNO) Annual Congress, held from November 21 to 24, 2024, in Houston. This prestigious event, known for bringing together the world’s top researchers, clinicians, and industry experts in the field of brain cancer research, is an ideal platform for Hemerion to present its pioneering …
In July 2024, Hemerion launched a participatory investment campaign in partnership with the Capital Cell platform. To answer investors’ questions, two webinars open to the public were organized in September 2024. At the end of September, Hemerion organized two webinars dedicated to its participative investment campaign organized with Capital Cell. The aim of these webinars …
In addition to a new financing round organized to prepare for the pivotal phases of clinical development of its Pentalafen / Heliance therapy, Hemerion is launching a crowdfunding campaign on the Capital Cell platform. Launch date: July 15, 2024, with the objective of raising €1.2 million. Since its founding in 2020, Hemerion has raised over …
The Pentalafen®/Heliance® combination therapy developed by Hemerion is designed to enhance the treatment of glioblastoma, the most prevalent brain cancer. This solution has already reached a significant level of clinical advancement and has recently been awarded a grant under the France 2030 investment plan, which will support its transition to the industrial and commercial phase. …
The Pentalafen® / Heliance® combination therapy developed by Hemerion is based on a technology tested in a phase 1 clinical trial sponsored by the University Hospital of Lille (INDYGO) between 2017 and 2021 in the treatment of glioblastoma. The results of the long-term follow-up of this clinical trial were published in the May 16, 2024 …
A first patient was treated in Pittsburgh, Pennsylvania in the United States in early April 2024 as part of the new clinical trial sponsored by Hemerion.This study (HTX-GBM-01) is designed to confirm the safety and feasibility of the Pentalafen® / Heliance® combination therapy in the treatment of glioblastoma, the most common and aggressive form of …